Skip to main content

Table 1 Patient characteristics

From: Single-center evaluation of prognostic factors for thymoma treated by surgery: a retrospective study

Characteristics
Age (years)
 Mean ± SD 61 ± 14.9
 Range 25–83
Sex, n(%)
 Male 30(50)
 Female 30(50)
Masaoka stage, n (%)
 I 47(78)
 II 4(7)
 III 3(5)
 IVa 4(7)
 IVb 2(3)
TNM stage, n(%)
 I 51(85)
 II 1(2)
 IIIa 2(3)
 IIIb 0(0)
 IVa 5(8)
 IVb 1(2)
Thymoma-related syndrome, n(%
 Myasthenia gravis 11(18)
 Pure Red Cell Aplasia 1(2)
 Lichen planus 1(2)
Histological type, n(%)
 A 6(10)
 AB 14(23)
 B1 11(18)
 B2 22(37)
 B3 7(12)
Tumor size (cm)
 Mean ± SD 5.4 ± 2.2
 Range 1.1–10
Operative approach, n(%)
 Median sternotomy 39(65)
 Lateral incision 1(2)
 Clamshell incision 5(8)
 Video assisted thoracoscopic surgery 15(25)
Operative procedure, n(%)
 Extended thymectomy 17(28)
 Thymomectomy 43(72)
Operative time (min)
 Mean ± SD 184 ± 79
 Range 40–362
Blood loss (g)
 Mean ± SD 94 ± 78
 Range 1–360
Postoperative treatment, n(%)
 Radiotherapy 12(20)
 Chemotherapy 4(7)
Resection status, n(%)
 Complete resection 53(88)
 Incomplete resection 7(12)
Initial relapse site (cases)
 Pleural dissemination 6
 Pulmonary metastasis 1
 Local 1
Treatment for recurrence (cases)(overlap)
 Surgery 1
 Chemotherapy  
  protocol  
   ADOC 2
   CBDCA+PTX 1
Cisplatin + Etoposide 1
 Radiation 4
  1. ADOC Adriamycin + cisplatin + vincristine + cyclophosphamide, CBDCA carboplatin, PTX paclitaxel, SD standard deviation, TNM tumor, node, metastasis